1-7 of 7
Sharyn D. Baker, PharmD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML

Daelynn R Buelow, PhD, Stanley Pounds, PhD, Yong-Dong Wang, Lei Shi, PhD, Yongjin Li, PhD, David Finkelstein, Sheila A Shurtleff, PhD, Geoffrey A. Neale, PhD, Hiroto Inaba, MD PhD, Raul C. Ribeiro, MD, Dominique Garrison, Shelley Orwick, BS, James S. Blachly, MD, John C. Byrd, MD, Karl Kroll, Tanja A. Gruber, MD PhD, Jeffrey E Rubnitz, MD PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 2838.
https://doi.org/10.1182/blood.V128.22.2838.2838
Published: 2016
Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3937.
https://doi.org/10.1182/blood.V128.22.3937.3937
Published: 2016
Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 3695.
https://doi.org/10.1182/blood.V126.23.3695.3695
Published: 2015
Journal Articles

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Jolieke G van Oosterwijk, PhD, Eric I Zimmerman, PhD, Yong-Dong Wang, PhD, Shelley Orwick, Aksana Vasilyeva, PhD, Katja Schuster, PhD, Abhijit Ramachandran, PhD, Hiroto Inaba, MD PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2014) 124 (21): 3620.
https://doi.org/10.1182/blood.V124.21.3620.3620
Published: 2014
Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD
Journal: Blood
Blood (2013) 122 (21): 2680.
https://doi.org/10.1182/blood.V122.21.2680.2680
Published: 2013
Journal Articles

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

Hiroto Inaba, MD, PhD, Jeffrey E Rubnitz, MD, PhD, Elaine Coustan-Smith, MS, Lie Li, Brian D Furmanski, PhD, Gerard P Mascara, Sheila A Shurtleff, PhD, Stanley B Pounds, PhD, Ching-Hon Pui, MD, Raul C Ribeiro, MD, Dario Campana, MD, PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2010) 116 (21): 1073.
https://doi.org/10.1182/blood.V116.21.1073.1073
Published: 2010
Journal Articles

Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.

Akira Shimada, MD, PhD, Shelley Orwick, Hiroyuki Fujisaki, MD., PhD, Dario Campana, MD., PhD, Sharyn D. Baker, PharmD., PhD
Journal: Blood
Blood (2008) 112 (11): 1630.
https://doi.org/10.1182/blood.V112.11.1630.1630
Published: 2008